103765-01-1 (左乙拉西坦杂质D,(R)-Levetiracetam)

(R)-左乙拉西坦;(R)-2-(2-氧代吡咯烷-1-基)丁酰胺;右乙拉西坦;左乙拉西坦杂质D;(alphaR)-alpha-乙基-2-氧代-1-吡咯烷乙酰胺;(R)-乙拉西坦;(R)-右乙拉西坦;左乙拉西坦EP杂质D;LEVETIRACCETAM的R-异构体;

(R)-2-(2-OXO-PYRROLIDIN-1-YL)-BUTYRAMIDE;(2R)-2-(2-oxopyrrolidin-1-yl)butanamide;(R)-2-(2-oxopyrrolidin-1-yl)butanamide;(R)-LevetiracetaM;1-Pyrrolidineacetamide,a-ethyl-2-oxo-, (aR)-;R-(+)-LEVETIRACETAM;1-Pyrrolidineacetamide,a-ethyl-2-oxo-, (R)-;UCB-L 060;(R)-Etiracetam;R-(+)-ETIRACETAM;levetiraccetam R-isomer;LevetiracetaM IMpurity D;Levetiracetam EP Impurity D;Levetiracetam Impurity enantiomer;(R)-2-(2-oxopyrrolidin-1- yl)butanamide;(αR)-α-Ethyl-2-oxo-1-pyrrolidineacetamide;LEVETIRACETAM IMPURITY D [EP IMPURITY];(R)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide;(S)-etiracetam;AKOS006272846;(2R)-2-(2-OXO-PYRROLIDIN-1-YL)BUTANAMIDE;(alphaR)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide;1-PYRROLIDINEACETAMIDE, .ALPHA.-ETHYL-2-OXO-, (.ALPHA.R)-;UCB-L-060;Etiracetam, R-(+)-;Etiracetam, (R)-;(2R)-2-(2-Oxopyrrolidin-1-yl)butanamide ((R)-Etiracetam);HPHUVLMMVZITSG-ZCFIWIBFSA-N;1-PYRROLIDINEACETAMIDE, .ALPHA.-ETHYL-2-OXO-, (R)-;DTXSID10146044;AS-78727;etiracetam, R-isomer;SCHEMBL61493;NS00000336;(2r)-2-(2-oxo-pyrrolidinyl)butanamide;(R)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (2R)-2-(2-Oxopyrrolidin-1-yl)butanamide; UCB-L 060; Levetiracetam Imp. D (EP); Levetiracetam Impurity D;CHEMBL150361;(aR)-a-Ethyl-2-oxo-1-pyrrolidineacetamide;Q417227;103765-01-1;BDBM50001546;73HC18Y1LW;A898867;(.ALPHA.R)-.ALPHA.-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE;LEVITIRACETAM;UNII-73HC18Y1LW;(R)-2-(2-oxopyrrolidin-1-yl)butyramide;Levetiracetam [INN];MLS003882549;SMR002533624;1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (R)-;

MFCD00867782

HPHUVLMMVZITSG-ZCFIWIBFSA-N

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m1/s1

O=C1CCCN1[C@@H](C(N)=O)CC